Home  >  News
you can get e-magazine links on WhatsApp.Click here
Policy & Regulations + Font Resize -

US FDA commissioner Margaret Hamburg to visit India

Our Bureau, Mumbai
Thursday, February 6, 2014, 11:40 Hrs  [IST]

Dr Margaret A Hamburg, commissioner of the US Food and Drug Administration (US FDA) is visiting India during February 10-18 to further strengthen cooperation between the FDA and its Indian regulatory counterparts. This is her first official trip to India.
During the trip, which will include visits to Delhi, Cochin, and Mumbai, Hamburg will meet with Indian policy and government leaders involved in the regulation of medical and food products exported to the United States. Indian regulators are important strategic partners to the FDA and regular engagement is essential. Currently, India is the second largest provider of finished drug products and the eighth largest exporter of food products to the United States.
“The FDA’s ongoing engagement with our regulatory counterparts in India is critical to our ability to effectively promote the health and safety of American and Indian consumers,” said commissioner Hamburg. “I look forward to enhancing our existing relationship and identifying additional opportunities for collaboration.”
The cooperation of United States and Indian food and drug officials is wide ranging, from sharing information on the conduct of clinical trials to jointly addressing product safety issues that may have an impact on both American and Indian consumers. Commissioner Hamburg will also meet with industry leaders in India to discuss the importance of maintaining high-quality standards in producing goods to ensure consumers have access to safe products.

The primary objective of FDA’s India Office, which opened in New Delhi in 2008, is to ensure that food and medical products exported from India to the US are safe, are good quality, and are effective. FDA’s goals in India are to obtain better and more robust information to help FDA officials in the various FDA headquarter Offices. In addition to FDA’s office in New Delhi, the FDA India Office staff is also located in Mumbai, India, which opened in 2009.


* Name :     
* Email :    
  Website :  
subodh j patil Feb 10, 2014 2:57 PM
if ranbaxy and wockhardt get a ban... why does jonson & jonson not get any comment on its baby powder defect???
Copyright © 2016 Saffron Media Pvt. Ltd |